Research Article
Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations
Table 2
Baseline characteristics of 24 patients with EGFR double mutations who received EGFR-TKI therapy.
| Characteristics | Total (%) | 19Del + L858R (%) | 19Del + T790M (%) | L858R + T790M (%) |
| Age (years) | | | | | <60 | 14 (58.3%) | 5 (45.5%) | 6 (75%) | 3 (60%) | ≥60 | 10 (41.7%) | 6 (54.5%) | 2 (25%) | 2 (40%) | Smoking | | | | | Yes | 8 (33.3%) | 7 (63.6%) | 0 (0%) | 1 (20%) | No | 16 (66.7%) | 4 (36.4%) | 8 (100%) | 4 (80%) | ECOG PS | | | | | 0-1 | 20 (83.3%) | 8 (72.7%) | 7 (87.5%) | 5 (100%) | 2 | 4 (16.7%) | 3 (27.3%) | 1 (12.5%) | 0 (0%) | Gender | | | | | Male | 13 (54.2%) | 9 (81.8%) | 3 (37.5%) | 1 (20%) | Female | 11 (45.8%) | 2 (18.2%) | 5 (62.5%) | 4 (80%) | EGFR-TKI line | | | | | First-line | 10 (41.7%) | 6 (54.5%) | 2 (25%) | 2 (40%) | After first-line | 14 (58.3%) | 5 (45.5%) | 6 (75%) | 3 (60%) | Pathology | | | | | Adenocarcinoma | 23 (95.8%) | 11 (100%) | 7 (87.5%) | 5 (100%) | Squamous carcinoma | 1 (4.2%) | 0 (0%) | 1 (12.5%) | 0 (0%) |
|
|